ReviewMaterials (Basel, Switzerland)2026
Understanding Polycaprolactone Degradation: Molecular Mechanisms and Implications for Biomedical Device Design.
Review in Materials (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Polycaprolactone (PCL) is a widely used biodegradable polyester in tissue engineering, drug delivery, and temporary implant design. While its favorable processability, biocompatibility, and low melting temperature are highly advantageous, its slow and condition-dependent degradation remains a major limitation for precise temporal control in biomedical applications. Despite extensive literature on PCL, a critical knowledge gap remains in linking fundamental molecular chain scission directly to macroscopic structural evolution, mechanical failure, and predictable in vivo device performance. To address this, this review provides a comprehensive synthesis of PCL degradation mechanisms, with a particular emphasis on PCL-bioceramic composites designed for hard tissue engineering. We elucidate the progressive degradation pathway-distinguishing between initial hydrolytic chain scission, oligomer formation, the generation of low-molecular-weight degradation products, and their subsequent metabolic fate under physiological conditions. Furthermore, this review critically evaluates how fundamental variables-specifically molecular weight, crystallinity, bioceramic fillers, device geometry, and physiological environments-alter degradation kinetics. By connecting molecular weight reduction to subsequent mass loss, thermal behavior, and mechanical deterioration, we establish a framework for understanding how structural reorganization and crystallinity evolution govern material failure. This review bridges the gap between simplified in vitro models and complex in vivo realities, supporting the rational design of composite biomedical devices with tailored, predictable resorption profiles.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.